International Journal of Pharmaceutical Compounding

A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of all issues and individual articles published by the Journal since 1997.

LEARN MORE

The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States

Author(s): Stephenson Kenna, Jones William, Stephenson Douglas M M

Issue: May/Jun 2006 - Hormone Replacement Therapy
View All Articles in Issue

Page(s): 175-183

The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States Page 1

The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States Page 2

The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States Page 3

The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States Page 4

The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States Page 5

The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States Page 6

The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States Page 7

The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States Page 8

The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States Page 9

Download in electronic PDF format for $75

Abstract: Prior to 1980, almost all drug advertising was directed to physicians, the parties responsible for prescribing medications to patients. Beginning in 1980, however, drug companies began advertising directly to patients by various means, specifically television and print advertisements and sponsorship of sports and similar events. During the last decade, as computers have become a common household item, the Internet is now another source of advertising for drug manufacturers. This change in advertising has been effective, since research has demonstrated that physicians’ prescribing decisions are, in fact, influenced heavily by patients’ requests for specific medications. In 1997, the US Food and Drug Administration devised specific guidelines for the television advertising of drugs produced by pharmaceutical manufacturers. Since youth and beauty have long been valued feminine qualities in the US, where menopausal women are assumed to suffer most from the effects of aging, pharmaceutical companies targeted women

Related Keywords: drug advertising, drug promotion, commercials, hormone replacement therapy, HRT, US Food and Drug Administration, FDA, women, aging, drug marketing

Related Categories: HRT, LEGAL, MARKETING, ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE

Printer-Friendly Version

Title/Author (Click for Abstract / Details / Purchase)	Issue/Page View/Buy
Related Articles from IJPC
The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States Stephenson Kenna, Jones William, Stephenson Douglas M M	May/Jun 2006 Pg. 175-183
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Allen Loyd V Jr	Sep/Oct 2017 Pg. 356
The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone Brunner Scott	Jan/Feb 2023 Pg. 22-23
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Allen Loyd V Jr	Jul/Aug 2016 Pg. 351 View Sample
A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 1 Gillson George R, Zava David T	Jul/Aug 2003 Pg. 250-256
Using Serum Hormone Analysis to Develop Hormone Replacement Therapy Regimens - Part 2 Ford Gina, Garcia Lea	Jan/Feb 2001 Pg. 52-54
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Miller David G	Jul/Aug 2015 Pg. 303-305
Menopausal Symptom Relief and Side Effects Experienced by Women Using Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 1 Deleruyelle Laura J	Sep/Oct 2016 Pg. 359-364
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Allen Loyd V Jr	Nov/Dec 2015 Pg. 487-488
Menopausal Symptom Relief and Side Effects Experienced by Women Using Compounded Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 2 Deleruyelle Laura J	Nov/Dec 2016 Pg. 447-454
Quality Control: Personal Protective Equipment for Use When Handling Hazardous Drugs Dillon L R	Jan/Feb 2020 Pg. 30-36
PostScription: Drug Disposal: Compounding Pharmacists' Involvement in the Prevention of Prescription Drug Misuse and Abuse Williams LaVonn A	Nov/Dec 2011 Pg. 526-527
Nonsterile Basics of Compounding: Using U.S. Food and Drug Administration-approved Commercial Products as Ingredients Allen Loyd V Jr	Nov/Dec 2023 Pg. 474-481
U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line Snow Stephen T, Stannard Robert W, Bellis Jennifer, Moss Carrie A	Jan/Feb 2019 Pg. 32-33
Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1 Allen Loyd V Jr	Sep/Oct 2015 Pg. 389-390
Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed Brunner Scott	Jul/Aug 2020 Pg. 296-297
The Role of Compounding Pharmacists During Drug Shortages Ofei Kelvin	Jul/Aug 2022 Pg. 298-301
Standard Operating Procedure: U.S. Food and Drug Administration Inspection--Releasing a Sample to the U.S. Food and Drug Administration Kupiec Tom, Kemp Jesse	Jul/Aug 2007 Pg. 326-327
The Politics of Hormone Replacement Therapy Allen Loyd V Jr	Jul/Aug 2007 Pg. 278-281
Bioidentical Hormone Replacement Therapy, Part 2, A Review of Wepfer Scott T	Jan/Feb 2002 Pg. 50-54
Return to Top